Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor

E. Kusumi, M. Kami, K. Yuji, T. Hamaki, N. Murashige, A. Hori, R. Kojima, Y. Kishi, S. W. Kim, J. Ueyama, S. Miyakoshi, Ryuji Tanosaki, S. Morinaga, S. Mori, Y. Heike, Y. Muto, S. Masuo, S. Taniguchi, Y. Takaue

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received RIST in the Tokyo SCT consortium from January 2000 to October 2002. The preparative regimens were fludarabine-based (150-180 mg/m2, n = 18) or cladribine-based (0.77 mg/kg, n = 2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatment-related mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived >100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35%. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0%, P = 0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients.

Original languageEnglish
Pages (from-to)697-702
Number of pages6
JournalBone Marrow Transplantation
Volume33
Issue number7
DOIs
Publication statusPublished - 2004 Apr
Externally publishedYes

Fingerprint

Unrelated Donors
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Antilymphocyte Serum
Whole-Body Irradiation
Transplants
Cladribine
Tokyo
Feasibility Studies
Methotrexate
Cyclosporine
Bone Marrow
Survival
Mortality

Keywords

  • Antithymocyte globulin
  • Intermediate-dose TBI
  • Matched unrelated donors
  • RIST

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. / Kusumi, E.; Kami, M.; Yuji, K.; Hamaki, T.; Murashige, N.; Hori, A.; Kojima, R.; Kishi, Y.; Kim, S. W.; Ueyama, J.; Miyakoshi, S.; Tanosaki, Ryuji; Morinaga, S.; Mori, S.; Heike, Y.; Muto, Y.; Masuo, S.; Taniguchi, S.; Takaue, Y.

In: Bone Marrow Transplantation, Vol. 33, No. 7, 04.2004, p. 697-702.

Research output: Contribution to journalArticle

Kusumi, E, Kami, M, Yuji, K, Hamaki, T, Murashige, N, Hori, A, Kojima, R, Kishi, Y, Kim, SW, Ueyama, J, Miyakoshi, S, Tanosaki, R, Morinaga, S, Mori, S, Heike, Y, Muto, Y, Masuo, S, Taniguchi, S & Takaue, Y 2004, 'Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor', Bone Marrow Transplantation, vol. 33, no. 7, pp. 697-702. https://doi.org/10.1038/sj.bmt.1704425
Kusumi, E. ; Kami, M. ; Yuji, K. ; Hamaki, T. ; Murashige, N. ; Hori, A. ; Kojima, R. ; Kishi, Y. ; Kim, S. W. ; Ueyama, J. ; Miyakoshi, S. ; Tanosaki, Ryuji ; Morinaga, S. ; Mori, S. ; Heike, Y. ; Muto, Y. ; Masuo, S. ; Taniguchi, S. ; Takaue, Y. / Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. In: Bone Marrow Transplantation. 2004 ; Vol. 33, No. 7. pp. 697-702.
@article{2cd3fafe245a47ea9db5178904e561f1,
title = "Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor",
abstract = "To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received RIST in the Tokyo SCT consortium from January 2000 to October 2002. The preparative regimens were fludarabine-based (150-180 mg/m2, n = 18) or cladribine-based (0.77 mg/kg, n = 2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatment-related mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived >100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35{\%}. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0{\%}, P = 0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients.",
keywords = "Antithymocyte globulin, Intermediate-dose TBI, Matched unrelated donors, RIST",
author = "E. Kusumi and M. Kami and K. Yuji and T. Hamaki and N. Murashige and A. Hori and R. Kojima and Y. Kishi and Kim, {S. W.} and J. Ueyama and S. Miyakoshi and Ryuji Tanosaki and S. Morinaga and S. Mori and Y. Heike and Y. Muto and S. Masuo and S. Taniguchi and Y. Takaue",
year = "2004",
month = "4",
doi = "10.1038/sj.bmt.1704425",
language = "English",
volume = "33",
pages = "697--702",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor

AU - Kusumi, E.

AU - Kami, M.

AU - Yuji, K.

AU - Hamaki, T.

AU - Murashige, N.

AU - Hori, A.

AU - Kojima, R.

AU - Kishi, Y.

AU - Kim, S. W.

AU - Ueyama, J.

AU - Miyakoshi, S.

AU - Tanosaki, Ryuji

AU - Morinaga, S.

AU - Mori, S.

AU - Heike, Y.

AU - Muto, Y.

AU - Masuo, S.

AU - Taniguchi, S.

AU - Takaue, Y.

PY - 2004/4

Y1 - 2004/4

N2 - To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received RIST in the Tokyo SCT consortium from January 2000 to October 2002. The preparative regimens were fludarabine-based (150-180 mg/m2, n = 18) or cladribine-based (0.77 mg/kg, n = 2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatment-related mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived >100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35%. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0%, P = 0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients.

AB - To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received RIST in the Tokyo SCT consortium from January 2000 to October 2002. The preparative regimens were fludarabine-based (150-180 mg/m2, n = 18) or cladribine-based (0.77 mg/kg, n = 2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatment-related mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived >100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35%. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0%, P = 0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients.

KW - Antithymocyte globulin

KW - Intermediate-dose TBI

KW - Matched unrelated donors

KW - RIST

UR - http://www.scopus.com/inward/record.url?scp=16544368076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544368076&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704425

DO - 10.1038/sj.bmt.1704425

M3 - Article

C2 - 14755317

AN - SCOPUS:16544368076

VL - 33

SP - 697

EP - 702

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -